Pharmaceutical companies only need patents for compositions of matter and general methods of use, right? Wrong. Discoveries can happen well into Phase III and IV and pharmaceutical companies should seek patent protection for those later-developed inventions. Partner and co-leader of the Biotechnology, Chemical, and Pharmaceutical patent prosecution team, Stephanie Lodise discusses how and why clinical stage patent protection can drive innovation in small molecule pharmaceutical development.

Questions & Comments: slodise@bakerlaw.com